Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
1993-7-9
|
| pubmed:abstractText |
Interleukin-1 alpha (IL-1 alpha) exerts antiproliferative effects on a human ovarian carcinoma cell line, NIH:OVCAR-3, which is resistant to clinically relevant concentrations of doxorubicin (DOX) and other chemotherapeutic agents. This action of IL-1 alpha depends on the presence of type I (80 kDa) receptors, although no quantitative relationship has been established between receptor occupancy and inhibition of cell growth. When NIH:OVCAR-3 cells were exposed to IL-1 alpha and DOX in combination, a mutual potentiation of the antiproliferative effects of the two agents was observed. This synergistic effect was not due to IL-1 receptor expression up-regulation by DOX, and receptor-dependent internalization of the cytokine was also unaffected. The involvement of IL-1 receptors is supported by the observation that synergism between the two agents was diminished (but not abolished) in the presence of a specific IL-1 receptor antagonist at concentrations blocking more than 75% of IL-1 alpha binding. DOX was found to significantly increase IL-1 alpha accumulation by NIH:OVCAR-3 cells after long-term (48 hr) exposure to the cytokine at 37 degrees, which might be due to increased nonspecific fluid phase uptake or to interference with cytokine degradation and/or release processes. The potent synergy of IL-1 alpha and DOX against ovarian carcinoma cells in vitro suggests that this drug combination may be effective against this disease in the clinic.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0006-2952
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
25
|
| pubmed:volume |
45
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2099-107
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:8512591-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8512591-Cell Division,
pubmed-meshheading:8512591-Doxorubicin,
pubmed-meshheading:8512591-Drug Interactions,
pubmed-meshheading:8512591-Drug Synergism,
pubmed-meshheading:8512591-Female,
pubmed-meshheading:8512591-Humans,
pubmed-meshheading:8512591-Interleukin-1,
pubmed-meshheading:8512591-Intracellular Fluid,
pubmed-meshheading:8512591-Iodine Radioisotopes,
pubmed-meshheading:8512591-Ovarian Neoplasms,
pubmed-meshheading:8512591-Protein Binding,
pubmed-meshheading:8512591-Receptors, Interleukin-1,
pubmed-meshheading:8512591-Tumor Cells, Cultured,
pubmed-meshheading:8512591-Up-Regulation
|
| pubmed:year |
1993
|
| pubmed:articleTitle |
Synergistic antiproliferative effects of interleukin-1 alpha and doxorubicin against the human ovarian carcinoma cell line (NIH:OVCAR-3).
|
| pubmed:affiliation |
Biochemical and Molecular Pharmacology Section, National Cancer Institute, NIH, Bethesda, MD 20892.
|
| pubmed:publicationType |
Journal Article
|